⌘K
Loading ticker…
Denali Therapeutics Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Denali Therapeutics Inc. Common Stock (DNLI) has a 3-month relative strength percentile of 80 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 67. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.3%, relative volume 3.64×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 80, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
DNLI is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 24.9% / 37.4%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
DNLI is held by 8 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $81M notional. Top 3 carry $208M.
Top 8 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $81M |
| IWMiShares Russell 2000 ETF | 0.09% | $67M |
| VBVanguard Small Cap ETF | 0.04% | $60M |
| XBIState Street SPDR S&P Biotech ETF | 0.73% | $54M |
| VBKVanguard Small-Cap Growth ETF | 0.09% | $33M |
| VXFVanguard Extended Market ETF | 0.04% | $32M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $4M |
| IWOiShares Russell 2000 Growth ETF | 0.01% | $1M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DNLI Jan avg: 7.36% median: 11.59% win: 75% σ: 23.91% n: 4 2022-04-12 → 2026-05-29 | DNLI Feb avg: -4.57% median: -6.44% win: 25% σ: 21.76% n: 4 2022-04-12 → 2026-05-29 | DNLI Mar avg: -9.66% median: -12.24% win: 25% σ: 9.62% n: 4 2022-04-12 → 2026-05-29 | DNLI Apr avg: -3.54% median: -2.50% win: 40% σ: 19.70% n: 5 2022-04-12 → 2026-05-29 | DNLI May avg: 7.17% median: 12.39% win: 80% σ: 17.30% n: 5 2022-04-12 → 2026-05-29 | DNLI Jun avg: 12.40% median: 13.41% win: 75% σ: 12.93% n: 4 2022-04-12 → 2026-05-29 (current) | DNLI Jul avg: 3.94% median: 1.90% win: 50% σ: 8.57% n: 4 2022-04-12 → 2026-05-29 | DNLI Aug avg: -6.69% median: -9.19% win: 50% σ: 14.50% n: 4 2022-04-12 → 2026-05-29 | DNLI Sep avg: 3.64% median: 3.00% win: 50% σ: 13.81% n: 4 2022-04-12 → 2026-05-29 | DNLI Oct avg: -3.51% median: -7.64% win: 25% σ: 10.57% n: 4 2022-04-12 → 2026-05-29 | DNLI Nov avg: 6.38% median: 4.81% win: 50% σ: 11.02% n: 4 2022-04-12 → 2026-05-29 | DNLI Dec avg: -7.66% median: -14.03% win: 25% σ: 15.86% n: 4 2022-04-12 → 2026-05-29 |